Publications in collaboration with researchers from Hospital Clinic Barcelona (35)

2023

  1. Best practices during COVID-19 pandemic in solid organ transplant programs in Spain

    Transplantation Reviews, Vol. 37, Núm. 1

  2. Erratum to “Recommendations for living donor kidney transplantation” (NEFROLOGIA (English Edition) (2022) 42(S2) (1–4), (S2013251422001444), (10.1016/j.nefroe.2022.01.009))

    Nefrologia

2022

  1. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients

    Transplantation, Vol. 106, Núm. 7, pp. 1430-1439

  2. Recommendations for living donor kidney transplantation

    Nefrologia, Vol. 42, pp. 5-132

2021

  1. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: Proof-of-concept study

    BMJ Open, Vol. 11, Núm. 10

  2. Hemodialysis Centers Guide 2020

    Nefrologia, Vol. 41, pp. 1-77

  3. Kidney transplant outcomes in elderly recipients with controlled donation after circulatory death or donation after brain death donors: a registry cohort study

    Transplant International, Vol. 34, Núm. 12, pp. 2507-2514

  4. Mortality in hemodialysis patients with covid-19, the effect of paricalcitol or calcimimetics

    Nutrients, Vol. 13, Núm. 8

2020

  1. Assessing the Limits in Kidney Transplantation: Use of Extremely Elderly Donors and Outcomes in Elderly Recipients

    Transplantation, Vol. 104, Núm. 1, pp. 176-183

  2. Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients

    Transplantation, Vol. 104, Núm. 11, pp. 2225-2233

  3. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. ACE2 and ACE in acute and chronic rejection after human heart transplantation

    International Journal of Cardiology, Vol. 275, pp. 59-64

  2. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients

    Transplantation Reviews, Vol. 33, Núm. 4, pp. 191-199

  3. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

    American Journal of Transplantation, Vol. 19, Núm. 11, pp. 3018-3034

2018

  1. Bloqueo del sistema renina-angiotensina-aldosterona en pacientes con enfermedad renal diabética avanzada

    Nefrologia, Vol. 38, Núm. 2, pp. 220-221

  2. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

    Journal of the American Society of Nephrology, Vol. 29, Núm. 7, pp. 1979-1991

2017

  1. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

    American Journal of Transplantation, Vol. 17, Núm. 7, pp. 1853-1867

  2. Serum osteoprotegerin in prevalent hemodialysis patients: Associations with mortality, atherosclerosis and cardiac function

    BMC Nephrology, Vol. 18, Núm. 1

  3. mTOR intersects antibody-inducing signals from TACI in marginal zone B cells

    Nature Communications, Vol. 8, Núm. 1

2016

  1. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation

    Transplant International, Vol. 29, Núm. 12, pp. 1317-1328